Clinical Trials
Cancer clinical trials help answer important questions about medical care in an effort to develop new and improved ways to treat all patients with cancer and those who will develop cancer in the future.
Find current clinical trials offered by Duke Cancer Institute:
Research Overview
Duke laboratory researchers and physician-scientists are pursuing a wide range of research projects to improve care and outcomes for patients with melanoma and other skin cancers. Here are few highlights:
- New surgical techniques for the treatment of malignant melanoma are available at Duke, including intraoperative lymphatic mapping and sentinel lymph node biopsy. This technique allows surgeons to remove a single lymph node to determine whether melanoma has spread from its primary site on the skin.
- Researchers at Duke have been instrumental in developing the role of positron emission tomography (PET) scanning in the staging of patients with malignant melanoma. This imaging technique allows physicians to pinpoint hot spots of melanoma that may have spread throughout the body and helps to distinguish benign from malignant tumors.
- Duke’s Pigmented Lesion Clinic and Melanoma Surveillance Program pioneered the use of CD-ROM technology to preserve a clear record of skin. Patients with numerous atypical (dysplastic) moles, personal history, or family history of melanoma are photographed from 33 different angles at the clinic. During future visits, the patient’s moles can be compared with the digital baseline images on the computer screen to discern if any changes took place since the last exam.
- Numerous national clinical trials are available to Duke patients, including some that attempt to define the importance of finding tumor cells so small they are detectable only with molecular biology techniques.
- Duke is working to develop a new generation of tumor vaccines. The new vaccines are designed to augment the function of the body’s main immune-fighting cell, the dendritic cell.
- Researchers are studying a class of drugs called interferons that kill melanoma cells. They are also determining the genes involved in that process in order to identify new targets for treating melanoma.
- Duke researchers are studying the origin of melanoma and have determined that the original melanoma mutation may occur in an adult stem cell. Current efforts are focused on identifying markers for these cells that will allow for the development of new diagnostic and therapeutic approaches.
- Duke surgeons are among the national leaders in developing novel techniques that allow regional delivery of new therapeutic agents to an extremity affected by melanoma. These regional treatments allow high doses of chemotherapy to be given without affecting the rest of the patient’s body.
- Researchers at Duke are leading international efforts to develop novel ways to treat regionally advanced melanoma. Using new drugs and novel delivery systems, Duke has become one of the largest regional therapy treatment programs in the country and is actively involved in leading national trials designed to give chemotherapy to an arm or a leg to treat locally recurrent or regionally recurrent melanoma that is confined to the extremities. Various novel treatment protocols include giving a high dose of chemotherapy into the extremity in conjunction with either hyperthermia or new targeted drugs to make the high dose chemotherapy more effective. During these treatments, the limb’s circulation is cut off from the rest of the body, which helps to minimize the side effects of the treatment.
- Duke is one of only a handful of centers using a reflectance confocal microscope to diagnose and study melanoma. The laser microscope lets researchers look into the skin to help determine if an area is skin cancer before a biopsy. The tool also allows one to see the blood moving through blood vessels and to study vascular morphology in tumors in real-time. There are approximately 30 confocal microscopes in use in the world.
Contact Us
|
Careers
|
Make a Gift
|
Site Map
